Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;146(1):157-162.
doi: 10.1007/s11060-019-03357-y. Epub 2019 Dec 3.

Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients

Affiliations

Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients

Aaron Michael Rulseh et al. J Neurooncol. 2020 Jan.

Abstract

Introduction: Glioblastoma (GBM) is the most common malignant primary brain tumor, and methods to improve the early detection of disease progression and evaluate treatment response are highly desirable. We therefore explored changes in whole-brain apparent diffusion coefficient (ADC) values with respect to survival (progression-free [PFS], overall [OS]) in a cohort of GBM patients followed at regular intervals until disease progression.

Methods: A total of 43 subjects met inclusion criteria and were analyzed retrospectively. Histogram data were extracted from standardized whole-brain ADC maps including skewness, kurtosis, entropy, median, mode, 15th percentile (p15) and 85th percentile (p85) values, and linear regression slopes (metrics versus time) were fitted. Regression slope directionality (positive/negative) was subjected to univariate Cox regression. The final model was determined by aLASSO on metrics above threshold.

Results: Skewness, kurtosis, median, p15 and p85 were all below threshold for both PFS and OS and were analyzed further. Median regression slope directionality best modeled PFS (p = 0.001; HR 3.3; 95% CI 1.6-6.7), while p85 was selected for OS (p = 0.002; HR 0.29; 95% CI 0.13-0.64).

Conclusions: Our data show tantalizing potential in the use of whole-brain ADC measurements in the follow up of GBM patients, specifically serial median ADC values which correlated with PFS, and serial p85 values which correlated with OS. Whole-brain ADC measurements are fast and easy to perform, and free of ROI-placement bias.

Keywords: Apparent diffusion coefficient; Diffusion-weighted imaging; Glioblastoma; Histogram analyses; Magnetic resonance imaging.

PubMed Disclaimer

Conflict of interest statement

JV is a consultant for Novocure.

Figures

Fig. 1
Fig. 1
Initial MR images in two subjects. Top row shows initial T1 SE post contrast (a), FLAIR (b) and ADC (c) in one subject that achieved PFS of 29.17 months and OS of 56.5 months. Bottom row shows initial T1 SE post contrast (a), FLAIR (b) and ADC (c) in one subject that achieved PFS of 3.67 months and OS of 12.67 months. SE spin echo, FLAIR fluid-attenuated inversion recovery, ADC apparent diffusion coefficient, PFS progression-free survival, OS overall survival
Fig. 2
Fig. 2
Partial (Pearson’s) correlation matrix between individual (RSD) variables. Values marked with an asterisk (*) were significant (p < 0.05). RSD, (linear) regression slope directionality (positive/negative).
Fig. 3
Fig. 3
Progression-free survival in subjects with a positive or negative median ADC regression slope. Colored dashed lines indicate 95% confidence interval, while black dash lines indicate the median survival in each group. ADC apparent diffusion coefficient
Fig. 4
Fig. 4
Overall survival in subjects with a positive or negative p85 ADC regression slope. Colored dashed lines indicate 95% confidence interval, while black dash lines indicate the median survival in each group. ADC apparent diffusion coefficient, p85 ADC 85th percentile value

References

    1. Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane (AU): Codon Publications; 2017. - PubMed
    1. Dehdashti AR, Hegi ME, Regli L, et al. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus. 2006;20:E6. doi: 10.3171/foc.2006.20.4.3. - DOI - PubMed
    1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomIDe vs maintenance temozolomIDe alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306–2316. doi: 10.1001/jama.2017.18718. - DOI - PMC - PubMed
    1. Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13. doi: 10.1016/j.jocn.2018.05.002. - DOI - PubMed
    1. Kondo M, Uchiyama Y. Apparent diffusion coefficient histogram analysis for prediction of prognosis in glioblastoma. J Neuroradiol. 2018;45:236–241. doi: 10.1016/j.neurad.2017.11.011. - DOI - PubMed

Substances